Pfizer's Business Development Transition: From "Revenues Now" To Pipeline Development
Pfizer will be active in business development, management said, but with a focus on building out the pipeline with bolt-on deals in the range of a "few billion." Gene therapy remains one area of interest.
You may also be interested in...
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.
The big pharma CEO reflected on his first year of leadership at Pfizer during the Forbes Healthcare Summit and talked about executing on a plan to deliver 6% growth through 2026.
The first generic versions of Pfizer's blockbuster pain medicine pregabalin have launched in the US. Pfizer has guided investors the company will return to growth in 2020 after cycling through the loss.